Atalanta Sosnoff Capital’s GSK GSK Stock Holding History

Atalanta Sosnoff Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$322K	Sell	6,144 -529	-8%	-$28K	0.01%	95
2026 Q1	$368K	Sell	6,673 -51	-0.8%	-$2.76K	0.01%	93
2025 Q4	$330K	Sell	6,724 -230	-3%	-$10.7K	0.01%	93
2025 Q3	$300K	Sell	6,954 -171	-2%	-$6.68K	0.01%	93
2025 Q2	$274K	Buy	7,125 +210	+3%	+$8.02K	0.01%	96
2025 Q1	$268K	Buy	6,915 +791	+13%	+$29K	0.01%	97
2024 Q4	$207K	Buy	6,124 +445	+8%	+$16K	﹤0.01%	97
2024 Q3	$232K	Hold	5,679	–	–	0.01%	100
2024 Q2	$219K	Sell	5,679 -218	-4%	-$9.17K	﹤0.01%	88
2024 Q1	$253K	Buy	+5,897	New	+$243K	0.01%	96
2015 Q3	–	Sell	-4,168	Closed	-$217K	–	99
2015 Q2	$217K	Buy	+4,168	New	+$235K	0.01%	98

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Atalanta Sosnoff Capital's GSK Position: Q2 2026 in Review

Atalanta Sosnoff Capital reduced its GSK (GSK) stake by 7.9% in Q2 2026, selling an estimated $28K and leaving 6,144 shares worth $322K. The position accounts for 0.01% of the portfolio, ranked #95.

Atalanta Sosnoff Capital first reported a position in GSK in Q2 2015 and has held it in 11 quarters since. The position peaked at $368K in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Atalanta Sosnoff Capital held 6,144 shares of GSK worth $322K as of Q2 2026.
Atalanta Sosnoff Capital sold 529 GSK shares in Q2 2026, an estimated $28K.
GSK made up 0.01% of Atalanta Sosnoff Capital's portfolio in Q2 2026, its #95 holding.
Atalanta Sosnoff Capital first reported a position in GSK in Q2 2015 and has held it in 11 quarters since.
Atalanta Sosnoff Capital's GSK position peaked at $368K in Q1 2026.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Atalanta Sosnoff Capital's 13F filing for Q2 2026, filed 12 Aug 2026.